Telix’s ProstACT Phase 3 Hits Primary Goals, Advancing Prostate Cancer Therapy

The success of Part 1 of the ProstACT study marks a pivotal moment for Telix Pharmaceuticals and the broader radiopharmaceutical sector. TLX591, an antibody-based radioligand therapy targeting Prostate-Specific Membrane Antigen (PSMA), is designed to treat patients with metastatic castration-resistant prostate cancer (mCRPC). Unlike its primary competitor, Novartis’s Pluvicto (177Lu-PSMA-617), which uses a small-molecule ligand, TLX591 utilizes a monoclonal antibody (mAb) to deliver its radioactive payload (Lutetium-177). This structural difference is significant; antibodies typically have longer circulation times and different biodistribution profiles, which Telix believes could lead to improved efficacy or more convenient dosing schedules. The achievement of primary objectives in this initial phase confirms that the antibody-based delivery system is performing as expected in a clinical setting, a critical hurdle for the platform's viability.

The primary objectives achieved in Part 1 of the study, often referred to as the SELECT or lead-in phase, were centered on safety, dosimetry, and the validation of a fractionated dosing regimen. Fractionated dosing—administering the therapy in smaller, more frequent doses—is intended to maximize the radiation dose delivered to the tumor while minimizing toxicity to healthy tissues, particularly the bone marrow and salivary glands. In radiopharmaceuticals, the therapeutic window is narrow; delivering enough radiation to kill cancer cells without causing irreversible damage to the patient's blood-producing marrow is the central challenge. The achievement of these objectives suggests that the fractionated approach is both safe and effective at achieving the desired radiation levels within the tumor microenvironment. This de-risks the program significantly as it moves into the larger, global efficacy phase of the Phase 3 trial, providing clinicians with confidence in the safety profile of this novel administration schedule.

“

Unlike its primary competitor, Novartis’s Pluvicto (177Lu-PSMA-617), which uses a small-molecule ligand, TLX591 utilizes a monoclonal antibody (mAb) to deliver its radioactive payload (Lutetium-177).

From a market perspective, Telix is positioning itself as a formidable challenger to Novartis in the multi-billion dollar PSMA-targeted therapy market. Telix already holds a strong position in the diagnostic space with Illuccix, its PSMA-PET imaging agent, which has seen rapid adoption since its FDA approval. By successfully developing TLX591, Telix would complete its theranostic offering—providing both the diagnostic tool to identify patients and the therapeutic tool to treat them. This integrated approach is increasingly seen as the gold standard in precision oncology, particularly in nuclear medicine, where patient selection via imaging is a prerequisite for treatment. The synergy between Illuccix and TLX591 could provide Telix with a significant commercial advantage, allowing for a seamless transition from diagnosis to therapy within the same clinical ecosystem.